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Abstract
In this study, the feasibility of high resolution magic angle spinning (HR MAS) magnetic resonance spectroscopy (MRS) of
small tissue biopsies to distinguish between tumor and non-involved adjacent tissue was investigated. With the current
methods, delineation of the tumor borders during breast cancer surgery is a challenging task for the surgeon, and
a significant number of re-surgeries occur. We analyzed 328 tissue samples from 228 breast cancer patients using HR MAS
MRS. Partial least squares discriminant analysis (PLS-DA) was applied to discriminate between tumor and non-involved
adjacent tissue. Using proper double cross validation, high sensitivity and specificity of 91% and 93%, respectively was
achieved. Analysis of the loading profiles from both principal component analysis (PCA) and PLS-DA showed the choline-
containing metabolites as main biomarkers for tumor content, with phosphocholine being especially high in tumor tissue.
Other indicative metabolites include glycine, taurine and glucose. We conclude that metabolic profiling by HR MAS MRS
may be a potential method for on-line analysis of resection margins during breast cancer surgery to reduce the number of
re-surgeries and risk of local recurrence.
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Introduction
Cancer is a major cause of death, with incidences predicted to
increase with the aging population [1]. Breast cancer is the most
common malignancy in women, and annually nearly 3000 women
receive surgery and additional treatment for breast cancer in
Norway [2]. In order to minimize the risk of local recurrences,
infiltrating tumors should be removed with free resection margins.
Currently, resection margins are evaluated by a pathologist after
surgery, and a significant number of patients is scheduled for re-
surgery [3,4]. In addition to the increased burden for the patient,
this also has a cost and capacity downside for the hospital.
Providing information to distinguish between tumor and non-
involved adjacent tissue during breast cancer surgery can help
surgeons delineate the tumor margins more accurately, thereby
significantly reducing the number of necessary re-surgeries.
The term metabolomics refers to the systematic studies of small-
molecular compounds of metabolism in cells, biofluids, organs or
tissues [5]. Metabolites are downstream products of metabolism,
and thereby a close measure of the phenotype of the biological
system being studied. Magnetic resonance spectroscopy (MRS) has
a long tradition for metabolite analyses, and the use of high
resolution magic angle spinning (HR MAS) enables analyses of
intact tissue samples [6]. This methodology is a promising tool
within cancer diagnostics and treatment evaluation [7], and has
already been applied in many studies of cancer [8–17]. Numerous
metabolites are detected in breast cancer biopsies, and the spectral
quality achieved using HR MAS is comparable to what is obtained
with liquid extracts [18]. The metabolic information contained in
the spectra can be used to establish prognostic and predictive
classifiers using appropriate multivariate statistical analyses, such
as principal component analysis (PCA) and partial least squares
(PLS) regression, which handles the highly co-variant nature of
MRS variables.
Recent technological advances facilitate automated analyses of
biological samples, and installations of MR equipment in close
proximity to the surgical theaters are in a growing phase. A case
report from colon adenocarcinoma supports that the time-
response of HR MAS is sufficiently fast for effective use on-line
during surgery [19]. Metabolic profiling thus has the potential to
become a method for rapid characterization of cancerous biopsies
in the operation theatre. Previous studies have shown the ability of
HR MAS to distinguish between cancerous and normal cervical
[20], colon [15,19] and prostate tissues [16,21]. A study using
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ultrasound-guided breast core-needle biopsies was recently pub-
lished [22]. However, the reported sensitivity for predicting cancer
was low, possibly due to the low number of included samples.
Furthermore, potential over-fitting due to multiple samples from
single subjects was not considered.
The aim of the current study was to evaluate the accuracy of
HR MAS MRS derived classifiers to distinguish breast tumor and
non-involved adjacent tissue for future on-line analyses within the
surgical theater using biopsies from a large biobank. For this
purpose, a robust validation scheme handling multiple samples
from single subjects has been implemented. Furthermore, the
classification impact of biopsies with low tumor content has been
investigated.
Methods
Patients and Tissue Samples
Cancer and non-involved tissue from breast cancer patients
undergoing surgery at St.Olavs Hospital, Trondheim, Norway and
Molde Hospital, Molde, Norway, have been consecutively enrolled
in a local biobank. The tissue samples are immediately frozen in
liquid nitrogen and stored until the MR analysis. The current
study includes 328 tissue samples from 228 patients with surgery
performed between 1999 and 2006. None of the patients received
neoadjuvant treatment prior to surgery. Information on diagnosis,
tumor grade, hormone receptor status, and lymph node in-
volvement was obtained from patient records, including pathology
reports. Axillary lymph node status was examined by sentinel node
procedure or axillary clearance. Histological grade was de-
termined according to guidelines of the Norwegian Breast Cancer
Group (NBCG), based on the Bloom and Richardson classification
system [23]. Estrogen receptor (ER) and progesterone receptor
(PgR) status were determined by immunohistochemistry ($10%
staining cancer cells considered receptor positive). Detailed patient
characteristics are described in Table 1. The study was approved
by the Regional Committee for Medical and Health Research
Ethics, Central Norway, and written informed consent was
obtained from all included patients.
HR MAS MRS
HR MAS MRS analyses of the tissue samples (n = 328) were
performed on a Bruker Avance DRX600 spectrometer (Bruker
BioSpin GmbH, Germany) equipped with a 1H/13C MAS probe
with gradient aligned with the magic angle axis. Frozen tissue
samples were cut to fit a MAS rotor (50 mL, median sample weight
16.2 mg) added phosphate buffered saline (PBS, 40 mL) based on
D2O containing trimethylsilyl 3-propionic acid sodium salt (TSP,
1.0 mM). Samples were spun at 5 kHz at a temperature of 4uC.
Proton spectra were acquired using a spin-echo Carr-Purcell-
Meiboom-Gill (CPMG) sequence (cpmgpr, Bruker) with 2 s water
suppression prior to a 90u excitation pulse. T2 filtering was
obtained using a delay of 1 ms repeated 136 times, resulting in an
effective echo time of 285 ms. A total of 128 scans over a spectral
region of 10 kHz were collected into 32 k points, giving an
acquisition time of 1.64 s. The spectra were Fourier transformed
into 128 K after 0.3 Hz exponential line broadening, and
chemical shifts were calibrated according to TSP (0 ppm). The
tissue specimens were fixed in 10% formalin and embedded in
paraffin after the HR MAS analysis. One 5 mm section was cut
from each paraffin block, stained with haematoxylin, erythrosine,
and saffron (HES), and examined microscopically by an experi-
enced pathologist. The relative areas of normal and neoplastic
epithelial elements were scored visually. An overview of the
biopsies and estimated tumor content is given in Table 2.
Data Preprocessing
The spectral region between 20.08 and 4.7 ppm was selected
for further processing. Values of negative spikes were replaced by
boundary values and the baseline offset was corrected by
subtracting the lowest value. Baseline trends were removed by
asymmetric least squares [24] with the smoothing parameter
l= 1e7, the asymmetry parameter p = 0.0001 and the order of
differences in penalty d = 2. Peak alignment was performed using
icoshift [25] with 39 manually chosen intervals and the highest
correlated spectrum as the reference as described in ref. [26]. The
area upfield from 3.0 ppm was removed after preprocessing.
Signals from ethanol pollutions at 3.691–3.642 ppm were deleted
together with fatty acid residuals at 4.200–4.400 ppm, resulting in
spectra of 2759 variables. The resulting spectra were mean-
normalized. Preprocessing of the data was performed in Matlab
7.6.0.
Multivariate Data Analysis
The variation of the data was explored by PCA [27]. PLS
discriminant analysis (PLS-DA) [28] was used to discriminate
cancer samples from adjacent non-involved tissue. PLS-DA was
executed after variable stability (VAST) scaling [29] of the data in
a supervised manner, with mean-centering instead of autoscaling
prior to multiplication of the scaling weights. The classification
performance was obtained using double cross-validation [30]
consisting of two nested leave-20%-out cross-validation loops. The
inner loop (repeated 20 times) was used to optimize the number of
latent variables (LVs) for PLS-DA, while the outer cross-validation
loop (repeated 80 times) was used to determine the classification
performance (accuracy, sensitivity and specificity). In order to
circumvent overoptimistic results it was assured that data from the
same patient were always present in one set, either the training,
test, or validation set. VAST scaling was applied during each
cross-validation loop on the training set and the resulting scaling
Table 1. Patient characteristics.
Age Median (range) 60.7 (29.6–91.8)
Tumor size Median (range) 2.0 (0–7)
Diagnosis IDC 175
ILC 21
Other* 32
Grade 1 26
2 100
3 80
Unknown 22
ER** status Positive 168
Negative 49
Unknown 11
PgR*** status Positive 132
Negative 80
Unknown 16
Lymph node status Positive 90
Negative 122
Unknown 16
*Ductal carcinoma in situ, mucinous carcinoma, several diagnoses.
**Estrogen receptor status.
***Progesterone receptor status.
doi:10.1371/journal.pone.0061578.t001
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parameters were applied independently to the test or validation
set. The loadings of the PLS-DA models were colored according to
their variable importance in projection (VIP) scores [31]. Further
validation of the significance of the PLS-DA classification results
were performed by permutation testing, and p-values ,0.05 were
considered significant [32].
Alternative ways of PLS-DA model making were investigated by
handling samples with very low tumor content in different ways;
either by defining samples with a low tumor cell content (between
0–4%) as adjacent non-involved tissue, or by defining all samples
with tumor cell content .0% as tumor tissue. Models were also
made by removing samples with low tumor cell content from the
training data and including them only in the test set (Table 3).
As an additional approach, classification was performed using
only the spectral region containing the choline-containing
metabolites (3.252–3.196 ppm) as input for the classification
model. This approach is relevant for the ongoing discussion
concerning choline metabolism in cancer.
PLS-DA was performed using the PLS_Toolbox 6.5.1 for
MATLAB (Eigenvector Research, Inc. Wenatchee, WA).
Results
Representative HR MAS MR spectra from breast biopsies with
high tumor cell content and normal adjacent tissue are given in
Figure 1. As previously reported [14], adipose tissue has an
immense impact on the spectral features due to the methylene and
methyl lipid protons giving rise to large signals centred around 1.3
and 0.9 ppm, respectively. None the less, the low molecular weight
metabolites are still visible in the spectra due to the T2-filtering
applied for MR acquisition.
A PCA score plot of the preprocessed spectra coloured
according to the tumor cell content of the samples is presented
in Figure 2A. A trend related to increasing tumor content is visible
from left to right along the first principal component (PC1,
explaining 40.1% of the variance of the spectra), showing that
differences in tumor content are contributing to the main variation
of the data set. The corresponding loading profile (Figure 2B)
shows that the samples with a low tumor content have higher levels
of glucose, while samples with a high tumor content have higher
levels of ascorbate, lactate, creatine, glycine, taurine and the
choline-containing metabolites (glycerophosphocholine (GPC),
phosphocholine (PCho), and free choline). The second PC,
explaining 16.3% of the variation, is separating samples based
on their level of PCho with a low PC2 score representing high
levels of PCho (not shown). Upon visual inspection, PC3 and
higher do not seem to explain any variance related to tumor
content.
The score plot from PLS-DA (Figure 3A) shows clear clusters of
normal adjacent tissue and cancerous tissue. The distinction is
mainly due to the variation described by LV1, attributed to higher
levels of ascorbate, lactate, creatine, glycine, taurine, and the
choline-containing metabolites in addition to lower levels of
glucose in the cancerous samples, a pattern similar to the one
observed by PCA. The distinction is less clear on LV2, which is
mainly attributed to variation in taurine and PCho levels among
the whole sample cohort. The PLS-DA classification results for
separating tumor and non-involved tissue are given in Table 3.
Various schemes for classifying the tumor and non-involved
adjacent tissue were investigated. Nearly all approaches lead to
accuracy, sensitivity and specificity around 90%. The best
classification result is achieved when defining all samples contain-
ing tumor cells (.0% tumor content) as tumor tissue, and training
the classification model leaving out biopsies with a low tumor
content (0%,tumor content ,5%). All classification results were
highly significant (p,0.001 by permutation testing).
Choline metabolism has a central role in breast cancer research.
Figure 4 shows the PCA score and corresponding loading (PC1)
plot from analysis of the choline spectral region (3.252–
Table 2. Tissue composition of the biopsies for the study cohort.
Number of samples/
patients Median (min-max) distribution of tissue type (%)
Tumor Fat Connective Glandular Necrotic
Normal adjacent tissue (Tumor
content 0% )
65/43 0 20(0–100) 60(0–100) 0(0–40) 0
Tumor content 1–4% 5/5 2(2–4) 5(0–98) 78(0–93) 0(0–15) 0(0–32)
Tumor content 5% 32/29 5 0 (0–47.5) 95 (47.5–95) 0(0–20) 0 (0–5)
Tumor content .5% 226/182 20 (7–95) 0(0–80) 70(0–93) 0(0–20) 0(0–30)
doi:10.1371/journal.pone.0061578.t002
Table 3. PLS-DA classification results for separating tumor and adjacent non-involved tissue.
Correct classification Sensitivity Specificity
Tumor ($5%TC) vs non-involved (,5% TC) 90% 83% 92%
Tumor (.0% TC) vs non-involved (0% TC) 89% 87% 89%
Tumor (.0% TC ) vs non-involved (0% TC)* 92% 91% 93%
Tumor (.0% TC) vs non-involved (0% TC)** 92% 90% 94%
*Samples with 0%,tumor content ,5% not used for model training, but included in testing only (5 samples, see Table 2).
**Samples with 0%,tumor content #5% not used for model training, but included in testing only (5+32 = 37 samples, see Table 2).
TC, tumor content.
doi:10.1371/journal.pone.0061578.t003
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Figure 1. HR MAS spectra and illustration of typical features observed in the corresponding HES images (200X). (A) Invasive ductal
carcinoma with an estimated tumor content of 80% in the analysed biopsy. (B) Invasive mucinous carcinoma with an estimated tumor content of 60%
in the analysed biopsy. (C) Normal breast tissue (adjacent to tumor). No tumor cells were detected, and the HES image shows the typical feature of
normal terminal lobular duct units. The poor signal to noise ratio in this spectrum is probably due to the high level of connective tissue (85%).
doi:10.1371/journal.pone.0061578.g001
Figure 2. Variation in tumor cell content as described by PCA. (A) The score plot of the pre-processed spectra, colored according to the
tumor cell content (%) of the corresponding biopsies. (B) The corresponding loading profile of PC1, explaining 40.1% of the total variation of the data.
b-Glc, b-glucose; Asc, ascorbate; Lac, lactate; Cr, creatine; Gly, glycine; Tau, taurine; GPC, glycerophosphocholine; PCho, phosphocholine; Cho, free
choline.
doi:10.1371/journal.pone.0061578.g002
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3.196 ppm), including only the signals from GPC, PCho, and
choline. The samples are labelled according to the tumor cell
content (%). In general, a high score for PC1 is associated with
high tumor content, and as shown by the loading profile, this is
attributed to relatively higher values of all the choline-containing
metabolites, especially PCho. 71.3% of the variation of the spectra
is explained in the first PC. PLS-DA modelling shows that the
choline region contains enough information to significantly
discriminate tumor and non-involved adjacent tissue (p,0.001
by permutation testing). However, the classification result report-
ing accuracy, sensitivity and specificity of 88%, 87% and 88%,
respectively, are lower than when including the complete low
molecular weight metabolic profile.
Discussion
In this study, we have proven the possibility to differentiate
breast tumor and non-involved tissue with high sensitivity and
specificity based on metabolic profiling by HR MAS MRS. Using
different approaches for classification, we showed accurate
discrimination of tumor and non-involved tissue also for samples
with low tumor cell content. This shows the possibility of applying
MR metabolomics for real-time determination of resection
margins during breast cancer surgery.
MR metabolomics has the advantage of being a rapid and low-
cost analysis method that can be performed while the patient is still
on the surgery table. The total process of preparing and analysing
the biopsy takes approximately 15 minutes, while data analysis of
the resulting spectra using previously developed and validated
classification models can be performed in under a minute. A free
resection margin determined during surgery can then be further
validated by histology after surgery. Due to the non-destructive
nature of HR MAS MRS, this can even be done on the same
tissue sample after HR MAS.
Tumor samples were shown to contain higher levels of
ascorbate, lactate, creatine, glycine, taurine, and the choline-
Figure 3. PLS- DA classification of tumor and non-involved tissue. (A) The score plot, separating tumor and non-involved tissue, and (B) the
corresponding loading profiles of LV1 and LV2. LV1 and LV2 explain 35.8% and 13.2% of the x-variation and 53.3% and 4.9% of the y-variation,
respectively. b-Glc, b-glucose; Asc, ascorbate; Lac, lactate; Cr, creatine; Gly, glycine; Tau, taurine; GPC, glycerophosphocholine; PCho, phosphocholine;
Cho, free choline.
doi:10.1371/journal.pone.0061578.g003
Figure 4. Variation in tumor cell content as described by PCA of the choline region. (A) The score plot of the choline-containing
metabolite region of the spectra, colored according to the tumor cell content (%) of the corresponding biopsies. (B) The corresponding loading
profile of PC1 explaining 71.3% of the total variation of the data.
doi:10.1371/journal.pone.0061578.g004
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containing metabolites, in addition to lower levels of glucose
compared to non-involved tissue, and this metabolic pattern was
associated with increasing amounts of tumor cells present in the
sample. An increased consumption of glucose and high accumu-
lated levels of lactate in tumor samples are consistent with the
Warburg effect [33,34]. Further, we showed that tumor and non-
involved tissue could be accurately discriminated using only the
choline-region as input for the classifier. The choline-containing
metabolites are of high interest in cancer research, and abnormal
choline metabolism is frequently observed [35]. Samples with high
tumor cell content had higher levels of all the choline-containing
metabolites compared to samples with low tumor cell content, with
PCho being especially elevated in tumors. This is reflecting the
increased proliferation rate in tumors, as choline is an important
constituent of cell membranes through the formation of phospha-
tidylcholine, and PCho and GPC are precursors and breakdown
products of this activity [36]. In some cancer cells, a relatively
large amount of glycolytic carbon is diverted into serine and
glycine metabolism through phosphoglycerate dehydro-genase
(PHGDH), which could explain the increased glycine concentra-
tion in the samples containing tumor cells [37]. The metabolic
reprogramming in cancer is comprehensive, and it is reasonable
that other metabolites such as creatine and taurine also are
affected. This may explain the observed multi-collinearity of the
metabolite changes.
This study was performed using a large patient cohort, with
a robust validation scheme correcting for the use of several
samples from the same patient. This step is important as several
biopsies from each patient will be analysed for determination of
surgical margins in a clinical setting. A motivation for investigating
the effect of various options of treating tissue samples with a low
tumor content was that these samples frequently in literature are
removed from the data set [38,39]. This is, however, not an
optimal approach if one wants to detect non-involved adjacent
tissue; even with the presence of very few tumor cells, a sample will
be considered tumor tissue in a clinical setting. The optimal
classification procedure was achieved when removing the samples
with low tumor cell content from model training, and including
these samples as tumor samples in the test data. A sensitivity and
specificity of 91% and 93%, respectively, were achieved. However,
only five spectra had tumor cell content between 1–4%, while 37
spectra had tumor cell content between 1–5%. Inclusion of more
samples with low tumor cell content is desirable in order to truly
test the prediction performance on such samples, as it might be
expected that tumor tissue close to the margins may contain a low
number of tumor cells.
Breast tissue biopsies contain a varying amount of lipids, and the
lipid signals present at 1.3 and 0.9 ppm were in many cases the
most intense signals in the spectra despite using a lipid-suppressing
CPMG sequence for MRS acquisition. In order to circumvent
dominance of the lipid signals during data analysis, the regions
containing these signals were removed from the spectra and the
data were normalized to equal total intensity prior to analysis.
Thus, the differing amount of breast lipids present in the samples is
partly corrected for, and emphasis is made to the low molecular
weight metabolites.
We have previously shown that the MR metabolic profile of
a tissue sample contains prognostic information beyond that of
traditional clinical parameters, with high levels of lactate and
glycine being indicative of lower 5-year survival rates [39,40].
Furthermore, the MR metabolic profile contains information
related to breast cancer subtypes [41,42]. In addition, MR
metabolic profiles have been correlated to hormone receptor status
and lymphatic spread [8,22,38]. This renders the possibility to use
the spectra acquired during surgery for prognostic assessment of
patients for further treatment planning after surgical removal of
the tumor.
For further assessment of using MR metabolomics as a clinical
tool for determining surgical margins, differentiation of cancer and
non-involved tissue should be examined by real-time analysis of
surgical biopsies from tumor border region, and the results should
be compared to histology. A more quantitative histopathology
assessment of the tumor content should be performed, by
investigating multiple sections throughout the biopsy after HR
MAS analysis. The effect of using either frozen or completely fresh
tissue should be investigated, as a study comparing the metabolic
profiles of fresh tissue to over-night freezing have shown moderate
changes in the metabolite concentrations due to freezing [43]. It is
possible that even better separation of cancer and non-involved
tissue could be achieved by using completely fresh, non-frozen
tissue samples.
Conclusion
Based on a large patient cohort (228 patients) we have shown
that metabolic profiling by HR MAS MRS can be used for
accurate classification of tumor and non-involved adjacent breast
tissue. The analysis has a time frame enabling on-line analysis of
resection margins during breast cancer surgery. The results were
obtained using a proper double cross validation procedure
assuring that the data originating from the same patient always
were present in one set, either the training, test, or validation set.
Moreover, using different visualization techniques we were able to
identify the metabolites related to the differentiation of tumor and
non-involved adjacent tissue.
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